

A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque

NCT06305559

Status	RECRUITING
Phase	Phase 3
Sponsor	NewAmsterdam Pharma
Enrollment	300 participants

Key Eligibility Criteria

Inclusion (5)

- Fasting serum LDL-C ≤ 70 mg/dL (≤ 1.81 mmol/L)
- Evaluable non-calcified plaque of at least 75 mm³ in the major epicardial coronary arteries
- BMI 18-40, inclusive
- Max tolerated lipid modifying therapy
- Estimated glomerular filtration rate ≥ 40 mL/min/1.73 m²

Exclusion (4)

- HbA1c $\geq 10.0\%$ (≥ 0.100 hemoglobin fraction) or a fasting glucose ≥ 270 mg/dL (≥ 15.0 mmol/L) at Screening
- Contraindications for CCTA
- History of coronary artery bypass graft
- Active liver disease

Locations (1 total)

NGMR, Hialeah, Florida, United States